ACVC Premium Access

Debating Oral P2Y12 inhibitors Use – are there differences across the Atlantic?

Event: ACVC 2021
Topic: Acute Coronary Syndromes
Session type: Debate Session
Date: 14 March 2021
Time: 00:30 - 01:10

Session

Become an ACVC member to access this resource

Become a member

Already a member? Sign in

6 presentations in this session

Pre-treatment with P2Y12 inhibitors in ACS is unnecessary and risky – PRO.

Speaker: Professor K. Huber (Vienna, AT)
Thumbnail

Pre-treatment with P2Y12 inhibitors in ACS is unnecessary and risky – CON.

Speaker: Professor C. Granger (Durham, US)
Thumbnail

Pre-treatment with P2Y12 inhibitors in ACS is unnecessary and risky – Discussion.

Thumbnail

Prasugrel and ticagrelor are equal in PCI for NSTEMI and STEMI - PRO.

Speaker: Professor R. Welsh (Edmonton, CA)
Thumbnail

Prasugrel and ticagrelor are equal in PCI for NSTEMI and STEMI - CON.

Speaker: Professor A. Kastrati (Munich, DE)
Thumbnail

Prasugrel and ticagrelor are equal in PCI for NSTEMI and STEMI - Discussion.

Thumbnail

4 speakers from this session

Professor Kurt Huber

Wilhelminen Hospital, Vienna (Austria)
40 presentations
5 followers

Professor Christopher B Granger

Duke University Medical Center, Duke Clinical Research Institute, Durham (United States of America)
11 presentations
0 follower

Professor Robert Welsh

Mazankowski Alberta Heart Institute, Edmonton (Canada)
15 presentations
0 follower

Professor Adnan Kastrati

German Heart Center Muenchen Technical University of Munich, Munich (Germany)
9 presentations
0 follower

This platform is supported by

logo Novo Nordisk